Friedrich Stölzel

Featured in: Favicon

nature.com

Articles

Safety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment - a retrospective, German-Swiss multicenter real-world data analysis - Bone Marrow Transplantation

Jan 13, 2025 | nature.com | Jörg Halter |Friedrich Stölzel |Nicolaus Kröger |Daniel Wolff |Francis Ayuk

AbstractBelumosudil is a first in class ROCK2-inhibitor approved by the FDA for the 3rd line treatment of chronic graft-versus-host disease (cGvHD). In this retrospective real-world analysis, we report safety and efficacy data of belumosudil treatment from 5 German/Swiss transplant centers. A total of 33 adult patients (median age 59 years) with moderate (n = 2) or severe (n = 31) cGvHD were treated on individual request due to lack of EMA approval.
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy - Blood Cancer Journal

Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more

AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy - Blood Cancer Journal

Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more

AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT |

Oct 24, 2024 | nature.com | Ana Alarcon Tomas |Edouard Forcade |Vladan Vucinic |Nicolaus Kröger |Lucía López Corral |Jan Vydra | +10 more

Chimeric antigen receptor (CAR) T-cells have ushered in a new era of adoptive cell immunotherapies and caused a paradigm shift in the treatment of relapsed and refractory B-cell lymphomas [1].
Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT | Bone Marrow Transplantation

Aug 26, 2024 | nature.com | Michael Daskalakis |Ron Ram |Emma Nicholson |Eugenio Galli |Friedrich Stölzel |Wolfgang Andreas Bethge | +5 more

Since summer 2018, three CAR-T cell products have been approved by the EMA to treat aggressive B-cell lymphomas, DLBCL, either de novo or tFL and PMBCL: tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) [1,2,3]. Tisa-cel, axi-cel, and liso-cel are approved for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) (and primary mediastinal large B-cell lymphoma (PMBCL) for axi-cel and liso-cel).
Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: Characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays

Jul 26, 2024 | fis.tu-dresden.de | Madina Sukhanova |Friedrich Stölzel |Kenan Onel |M. Kamran Mirza

Myeloid sarcoma (MS) is a presentation of acute myeloid leukemia (AML) as a tumor mass outside of the bone marrow. Viable cells from MS are frequently unavailable for cytogenetic studies. We therefore investigated whether chromosomal microarray analysis (CMA) using formalin-fixed paraffin-embedded (FFPE) tissues can detect clinically important genetic abnormalities in MS.
Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients | Blood Cancer Journal

May 1, 2024 | nature.com | Ali Bazarbachi |Jürgen Finke |Nicolaus Kröger |Martin Bornhauser |Friedrich Stölzel |Peter Dreger | +4 more

AbstractSecond allogeneic stem cell transplantation (alloSCT2) is among the most effective treatments for acute myeloid leukemia (AML) relapse after first alloSCT (alloSCT1). Long-term EBMT registry data were used to provide large scale, up-to-date outcome results and to identify factors for improved outcome.
Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT | Bone Marrow Transplantation

Mar 18, 2024 | nature.com | Romain Guièze |Johannes Schetelig |Jakob Passweg |Jürgen Finke |Mutlu Arat |Friedrich Stölzel | +7 more

AbstractManagement of Richter transformation (RT) is particularly challenging, with survival estimates <1 year. We report on outcomes of 66 RT patients undergoing allogeneic-HCT (allo-HCT) between 2008 and 2018 registered with the EBMT. Median age at allo-HCT was 56.2 years (interquartile range (IQR), 51.3–63.1). Median time from RT to allo-HCT was 6.9 months (IQR, 4.9–11) and 28 (42.4%) were in complete remission (CR).
Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison | Bone Marrow Transplantation

Feb 20, 2024 | nature.com | Dietrich Wilhelm Beelen |Friedrich Stölzel |Fabio Ciceri |Wolfgang Andreas Bethge |Peter Dreger |Donal McLornan | +2 more

AbstractA randomized study (acronym: MC-FludT.14/L Trial II) demonstrated that fludarabine plus treosulfan (30 g/m²) was an effective and well tolerated conditioning regimen for allogeneic hematopoietic cell transplantation (allo-HCT) in older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial - Nature Cancer

Oct 2, 2023 | nature.com | Peter-Martin Bruch |Tobias Roider |Claudia D. Baldus |Hubert Serve |Daniel Hübschmann |Carsten Müller-Tidow | +3 more

AbstractEx vivo drug response profiling is a powerful tool to study genotype–drug response associations and is being explored as a tool set for precision medicine in cancer. Here we conducted a prospective non-interventional trial to investigate feasibility of ex vivo drug response profiling for treatment guidance in hematologic malignancies (SMARTrial, NCT03488641). The primary endpoint to provide drug response profiling reports within 7 d was met in 91% of all study participants (N = 80).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Friedrich Stölzel

Articles

Safety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment - a retrospective, German-Swiss multicenter real-world data analysis - Bone Marrow Transplantation

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy - Blood Cancer Journal

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy - Blood Cancer Journal

Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT |

Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT | Bone Marrow Transplantation

Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: Characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays

Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients | Blood Cancer Journal

Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT | Bone Marrow Transplantation

Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison | Bone Marrow Transplantation

Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial - Nature Cancer

Contact details

Emails

Socials & Sites